Actively Recruiting
The Study of Association of Helicobacter Infections in Biliary Tract Cancers
Led by Institute of Liver and Biliary Sciences, India · Updated on 2025-12-12
250
Participants Needed
1
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Biliary tract carcinoma (BTC) includes gallbladder carcinoma, hilar cholangiocarcinoma, and distal cholangiocarcinoma, intrahepatic cholangiocarcinoma. Chronic infections of the biliary tract are major drivers of cancer. Helicobacter species is one of the most established pro-oncogenic pathogens for gastric malignancy. In addition to H Pylori, H.bilis and H.hepaticus have a significantly higher incidence in bile from biliary tract and gallbladder cancer patients than in patients with gallstones/cholecystitis. This, together with the high prevalence of gallstones, makes it important to evaluate the role of Helicobacter in biliary tract cancers. This study aims to compare the prevalence of Helicobacter sp.(pylori, bilis, hepaticus). This study will include biliary tract carcinoma patients, benign biliary disease patients, high risk conditions for malignancy and Voluntary healthy liver donors with no gallbladder pathology. HPE samples will be assessed and association of Helicobacter sp will be studied among all 4 arms. All the included samples will be assessed for Helicobacter species using giemsa stain and DNA PCR. Results will be studied to compare the prevalence of Helicobacter sp. in Biliary tract malignancy and benign biliary diseases.
CONDITIONS
Official Title
The Study of Association of Helicobacter Infections in Biliary Tract Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biliary tract carcinoma patients who underwent resection
- Patients undergoing cholecystectomy for benign biliary disease
- Voluntary healthy liver donors with no gallbladder pathology
- Patients undergoing cholecystectomy for conditions with high risk of malignancy
You will not qualify if you...
- Patients who have taken H.pylori eradication therapy in the last three months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
ILBS
New Delhi, National Capital Territory of Delhi, India, 110070
Actively Recruiting
Research Team
N
Niyatank Tyagi, MS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here